Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CTLA4
REST API REST API
Homo sapiens
CTLA4 is differentially expressed in 195 experiments: 88 organism parts: lung, bone marrow, ... (86 more);, 154 disease states: normal, cervical carcinoma, ... (152 more);, 67 cell types 151 cell lines 25 compound treatments and 72 other conditions.
Synonyms CD, CD152, CELIAC3, GSE, CD28, ICOS
Orthologs Q1XDY5_CHICK (Gallus gallus)   Ctla4 (Mus musculus)   Q28090_BOVIN (Bos taurus)   Ctla4 (Rattus norvegicus)   CD28 (Danio rerio)   CTLA4_CANFA (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, CTLA4, Ig_V-set_subgr
Gene Ontology Term plasma membrane, membrane, Golgi apparatus, positive regulation of apoptosis, external side of plasma membrane, integral to plasma membrane, immune response, perinuclear region of cytoplasm, response to DNA damage stimulus, B cell receptor signaling pathway, negative regulation of regulatory T cell differentiation, clathrin-coated endocytic vesicle, negative regulation of B cell proliferation, T cell costimulation
Gene-Disease Assocation HASHIMOTO THYROIDITIS, AUTOIMMUNE DISEASE, GRAVES DISEASE, HEPATITIS B VIRUS, SUSCEPTIBILITY TO, CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3, DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12, SYSTEMIC LUPUS ERYTHEMATOSUS; SLE
UniProt Accession P16410, Q8TDA6, O95653, Q0Q5F1, Q9BZK2, E9L3G3, E9L3G1, E9L3G0
Search EB-eye ENSG00000163599
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-TABM-130, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, E-MTAB-62, ... (16 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
NALM1
1
E-MTAB-37
SKMES1
1
E-MTAB-37
Capan1
1
E-MTAB-37
AsPC1
1
1
E-MTAB-37
SW1353
1
E-MTAB-37
145 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (33 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-11755, E-GEOD-7307
CD4+ T cell
2
3
E-GEOD-16190, E-GEOD-6740, E-GEOD-19069, E-AFMX-5, E-TABM-145 ... (5 experiments)
LCC
1
E-GEOD-19188
M1 macrophage
1
E-GEOD-5099
CD326negCD56+ cell
1
1
E-GEOD-21668
centrocyte
1
E-TABM-702
61 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-MEXP-2069, E-GEOD-9692, E-GEOD-20602, ... (41 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-GEOD-2685, E-GEOD-15460
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
cervical carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5823
Burkitt's lymphoma
1
E-MTAB-37
no atrial fibrillation
1
E-GEOD-2240
148 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
none
3
4
E-MEXP-1601, E-GEOD-5824, E-GEOD-7400, E-MEXP-1958, E-GEOD-5230, ... (7 experiments)
vanadium pentoxide
1
E-GEOD-5339
ethanol
1
E-MEXP-2241
5-aza-2'-deoxycytidine
3
1
E-GEOD-5230
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
no estradiol
1
E-GEOD-20081
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-2666, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-361

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-TABM-321, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-12773, E-GEOD-20540, E-GEOD-10315, E-MEXP-1103 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-TABM-740, E-MEXP-2069, E-TABM-26, E-TABM-118, ... (27 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22229, E-GEOD-26495, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-6532, E-GEOD-4922

Processing time: 0.436 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM